Recomendaciones Ecuatorianas Para Pacientes con Esclerosis Múltiple en Relación a Pandemia Por Coronavirus (COVID-19)

Correa-Díaz, Edgar Patricio; Ortiz-Yépez, M. A.; Barrera-Madera, R. A.; Santos-Gamarro, M. J.; Miño-Zambrano, J. E.; Caiza-Zambrano, Francisco; Paredes-González, Victor; Chong, María Gabriela Acuña; Toral-Granda, A. M.; Jácome-Sánchez, Elisa Carolina

doi:10.46997/revecuatneurol29100012

Cited by 4 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another drug of high effectiveness, natalizumab, is the only one considered as low risk for contracting or presenting severe forms of COVID-19 [22][23][24] because it does not interfere with the lymphocyte function. Other drugs with moderate risk for COVID-19 due to their modest immunosuppressive effect are those with a modulatory effect of the S1P receptor (fingolimod, siponimod, and ozanimod) and anti-CD20 (ocrelizumab and rituximab) [22][23][24]. S1P modulators are capable of reducing peripheral lymphocytes; these agents could potentially raise the susceptibility to coronavirus infection as evidenced by the increased predisposition to other viral infections [21].…”

Section: Management Strategies Of Ms Patients and Sars-cov-2 Infectionsmentioning

confidence: 99%

“…Finally, the greatest infection risk has been suggested for highly effective treatments in the management of MS due to their marked effect on the lymphocyte population, for instance, alemtuzumab or cladribine, primarily due to lymphopenia described as associated withCOVID-19 [24]. Therefore, they are classified as the drugs with the highest risk for infection by the new coronavirus [20,22,23,25].…”

Section: Management Strategies Of Ms Patients and Sars-cov-2 Infectionsmentioning

confidence: 99%

“…Considerations on the use of DMT in MS and COVID-19 are suggested in recently diagnosed patients by starting with first-line treatments, such as glatiramer acetate, interferons, dimethyl fumarate, or with teriflunomide, in mild cases without factors which would indicate a bad prognosis [20,24]. For those with highly active MS and in cases positive to JCV antibodies, the use of natalizumab is recommended over alemtuzumab, cladribine, or ocrelizumab.…”

Section: Management Of Dmt In Ms Patients During the Covid-19 Pandemicmentioning

confidence: 99%

“…In DMT patients, the International Multiple Sclerosis Federation recommends continuing treatment together with general measures of social isolation [24] and special monitoring of lymphocyte counts for those undergoing treatments with S1P receptor modulators, dimethylfumarate, teriflunomide [24]. In the case of natalizumab, it is not recommended to modify the frequency or dose of treatment considering that the risk of reactivation may be greater than the risk of contracting the viral infection, although it is possible to consider administration in prolonged intervals [22].…”

Section: Management Of Dmt In Ms Patients During the Covid-19 Pandemicmentioning

confidence: 99%

“…In cases of DMT with the anti-CD20 monoclonal antibody, it is recommended to delay the doses until reducing the risk of coronavirus infection [24] and use rituximab. Furthermore, it is recommended to shift it from two to three months and avoid having patients attend medical care centers [22] while taking ocrelizumab.…”

Section: Management Of Dmt In Ms Patients During the Covid-19 Pandemicmentioning

confidence: 99%

See 4 more Smart Citations

SARS-CoV-2 Infection and Risk Management in Multiple Sclerosis

Fé

Suárez

Campos³

et al. 2021

Diseases

View full text Add to dashboard Cite

The novel coronavirus can cause a severe respiratory disease with impact on the central nervous system, as has been reported by several medical health services. In the COVID-19 pandemic caused by the SARS-CoV-2 neurotrophic virus, neurologists have focused their attention on the early identification of suggestive manifestations of the neurological impact of the disease. In this context, they are exploring related chronic disease and the possibility of achieving a more effective understanding of symptoms derived from COVID-19 infection and those derived from the course of preexisting neurological disease. The present review summarizes evidence from the infection with SARS-CoV-2 and the management of the risks of multiple sclerosis and how it is related to the risks of general comorbidities associated with COVID-19. In addition, we reviewed other factors characteristic of MS, such as relapses, and the maximum tolerated dose of treatment medications from clinical and experimental evidence.

show abstract

Section: Management Strategies Of Ms Patients and Sars-cov-2 Infectionsmentioning

confidence: 99%

Section: Management Strategies Of Ms Patients and Sars-cov-2 Infectionsmentioning

confidence: 99%

Section: Management Of Dmt In Ms Patients During the Covid-19 Pandemicmentioning

confidence: 99%

Section: Management Of Dmt In Ms Patients During the Covid-19 Pandemicmentioning

confidence: 99%

Section: Management Of Dmt In Ms Patients During the Covid-19 Pandemicmentioning

confidence: 99%

See 3 more Smart Citations

SARS-CoV-2 Infection and Risk Management in Multiple Sclerosis

Fé

Suárez

Campos³

et al. 2021

Diseases

View full text Add to dashboard Cite

show abstract

Esclerosis múltiples

Morales Coloma,

Prieto Ulloa,

Naranjo Guerrero

et al. 2023

RECIMUNDO

View full text Add to dashboard Cite

La esclerosis múltiple (EM) es una enfermedad inflamatoria crónica del sistema nervioso central (SNC), con carácter autoinmune, desmielinizante, que impide el funcionamiento normal de la sinapsis. Lo que acarrea déficits motores y sensitivos que pueden durar días o semanas y ser total o parcialmente reversibles. La presente investigación se enmarca dentro de una metodología de tipo bibliográfica documental. Ya que es un proceso sistematizado de recolección, selección, evaluación y análisis de la información, que se ha obtenido mediante medios electrónicos en diferentes repositorios y buscadores tales como Google Académico, Science Direct, Pubmed, entre otros, empleando para ellos los diferentes operadores booleanos y que servirán de fuente documental, para el tema antes planteado. Por ser la esclerosis múltiple una patología autoinmune, necesita un tratamiento focalizado en la persona, con el objetivo de lograr el mayor bienestar posible, ya que la esclerosis múltiple puede presentarse de 4 formas diferentes y no necesariamente el manejo debe ser el mismo, ya que también hay que considerar las comorbilidades que ya tenga el paciente, el tratamiento puede estar enfocado en inmunosupresores, AINES, corticoesteroides, entre otros. En cuanto al diagnóstico los criterios de McDonald son los universalmente aceptados, la sintomatología puede ser diversa, pudiendo generar fatiga, problemas cognitivos, problema de visión, dolor en articulaciones, entre otros.

show abstract

The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic

et al. 2021

View full text Add to dashboard Cite

A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course after infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). However, the recently published data have shown that MS patients do not have a higher risk for severe COVID-19. Although there is no indication that patients with MS and immunomodulatory/immunosuppressive therapy are generally at a higher risk of severe COVID-19, it is currently being emphasized that the hazards of poorly treated MS may outweigh the putative COVID-19 dangers. In this review, we discuss the challenges and considerations for MS patients in the COVID-19 pandemic.

show abstract

Recomendaciones Ecuatorianas Para Pacientes con Esclerosis Múltiple en Relación a Pandemia Por Coronavirus (COVID-19)

Cited by 4 publications

References 8 publications

SARS-CoV-2 Infection and Risk Management in Multiple Sclerosis

SARS-CoV-2 Infection and Risk Management in Multiple Sclerosis

Esclerosis múltiples

The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic

Contact Info

Product

Resources

About